New research looks to reduce side effects in commonly used drugs

New research from The Australian National University (ANU) has drilled down to the molecular level to find similarities across six pharmaceutical drugs used in pain relief, dentist anaesthetic, and treatment of epilepsy, in a bid to find a way to reduce unwanted side-effects. One in five Australians experience chronic pain, and 250,000 Australians live with epilepsy, 40 per cent of which are children.

Until now, researchers have known that drugs which treat pain and epilepsy are effective, some of which have even been used clinically since the 1950s. But molecular details of how they work and why they cause side effects have not been studied until relatively recently, thanks to new technology.

Dr Amanda Buyan from the ANU Research School of Biology said thanks to the National Computational Infrastructure (NCI) super computing power at ANU, researchers are now able to run bigger and more complex simulations to get a better picture of what is going on.

"Understanding the molecular detail of how they work gives us clues to why these drugs might be effecting one part of the body that we want, but may also effect part of the body that we don't want to effect," she said.

"Understanding this can hopefully inform future scientists working on drug discovery that this is how we think these types of drugs work."

Dr Buyan hopes the research will better inform scientists about the possibility of changing the structure of existing drugs, or in designing a new drug to make sure that it does what is intended without the side effects.

"I hope that it leads to drugs being changed slightly to be more specific or lead to a different avenue that might be more fruitful."

Buyan A, Sun D, Corry B.
Protonation state of inhibitors determines interaction sites within voltage-gated sodium channels.
Proc Natl Acad Sci U S A. 2018 Feb 21. doi: 10.1073/pnas.1714131115.

Most Popular Now

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...

Pfizer reaches a global agreement with AbbVie

Pfizer Inc. (NYSE:PFE) has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar. Under ...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

GSK reaches agreement to acquire TESARO, an oncolo…

GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...